A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Bempedoic acid/ezetimibe (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Esperion Therapeutics
- 02 Oct 2019 Status changed from active, no longer recruiting to completed.
- 29 Aug 2019 Status changed from recruiting to active, no longer recruiting, according to a Daiichi Sankyo Europe media release.
- 29 Aug 2019 Primary endpoint (LDL-C lowering FDC vs. Ezetimibe) has been met, according to a Daiichi Sankyo Europe media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History